OBI has filed the application of a Phase I/II human clinical trial for OBI-992 TROP2 ADC to TFDA

1.Date of occurrence of the event:2024/05/30 2.New drug name or code:OBI-992 TROP2 ADC 3.Indication: OBI-992 is an antibody drug conjugate (ADC) for cancer treatment that is based on TROP2 to target cancer cells. ADC releases a small molecule payload through the specificity of the antibody and directly deploys cytotoxic molecule at the targeted cancer cells. […]